ARAY vs AZN

ARAY's Piotroski F-Score of 4/9 indicates weak financial health, with a critical debt-to-equity ratio of 2.90 and negative ROE of -70.32%, signaling significant operational and solvency concerns. Despite a 16.8% year-over-year revenue growth, the company remains unprofitable with a negative profit margin of -8.15% and erratic earnings performance, including a -650% YoY EPS decline. The stock trades at a deeply discounted price-to-sales of 0.10 and price-to-book of 0.82, but this reflects severe market skepticism due to persistent losses and high financial risk. Analysts have a target price of $2.52, implying a potential 580% upside, yet this is based on minimal coverage and no consensus, underscoring speculative risk. The lack of insider activity and technical bearishness further reinforce a high-risk profile.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.